• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

R&D Portfolio Update February 2019: DNDi Chagas disease programme

Home > News

R&D Portfolio Update February 2019: DNDi Chagas disease programme

Chagas patient in the hospital with a nurse
21 Feb 2019
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi aims to deliver:

  • A new benznidazole monotherapy regimen.
  • A new benznidazole and fosravuconazole combination treatment regimen.
  • A new fexinidazole monotherapy regimen.
  • A new chemical entity to be tested in clinical trials for treatment of patients with chronic Chagas disease.

DNDi’s current Chagas disease portfolio includes:

Research

Discovery

Four projects in the discovery phase:

  • Chagas hit-to-lead (H2L): DNDi has continued its efforts in screening chemically diverse libraries for identification and confirmation of new hits that could progress and feed the H2L pipeline. In 2018, a new partnership was established with the Drug Discovery Unit from Dundee University in Scotland and GSK to jointly characterize and progress new promising hits.
  • Booster hit-to-lead (H2L): In 2018, the Japanese pharmaceutical company Astellas Pharma Inc. joined the NTD Drug Discovery Booster, becoming the eighth company in the consortium. The project conducts multilateral, simultaneous searches of millions of compounds based on an active seed supplied by DNDi and uses computational approaches to refine the search iteratively. Since its creation in 2015, the Booster project has launched 45 iterations around 22 seed compounds, with the result that 13 hit series have been released, of which six have progressed to in vivo proof-of-concept studies for Chagas and/or leishmaniasis.
  • Daiichi-Sankyo Chagas hit-to-lead: This project, which ended in September 2018, aimed to identify at least one progressable lead series meeting DNDi lead-stage criteria for Chagas disease and/or visceral leishmaniasis. The project milestone was reached with the identification of a progressable Chagas lead series with proven in vivo efficacy. Daiichi Sankyo and DNDi are now looking for funding to progress this promising series for Chagas disease in 2019.
  • Chagas C205 series: This series is part of the GSK/DDU/DNDi discovery collaboration portfolio, following a research agreement made in early 2018. Work on the series has concentrated on safety profiling and exploratory toxicology for the selected front-runners. Decision on if and how to proceed will be made once the complete BENDITA trial data are available. 

 

Translation

Translation

Three projects in the translation phase:

  • Biomarkers: Current work is focusing on raising awareness among Chagas stakeholders about the need for biomarkers, with particular emphasis on regulatory aspects and the biomarker development process. Presentation of the Chagas Clinical Data Sharing Platform project (IDDO/DNDi) in plenary at the 2018 Chagas Platform Meeting in Santa Cruz was well received by clinicians. In parallel, the development of a prototype assay is ongoing for newly identified biomarkers – Apo A1 and Fbn fragments issued from a collaboration with McGill University – with InfYnity Biomarkers. The analysis of the NHEPACHA study data is pending and will be presented at the XV Chagas Disease Workshop organized by the Institute for Global Health Barcelona in March 2019.  
  • Benznidazole new regimens (‘Bendita’ study): This proof-of-concept trial was completed in the third quarter of 2018 and results will be available in early 2019. A total of 210 patients were recruited for this study, which was conducted in three sites in Bolivia and aims to improve efficacy, safety and tolerability of treatment of adults with chronic indeterminate Chagas. The trial assessed the efficacy of different doses of benznidazole in monotherapy and in combination with fosravuconazole. The primary measure of efficacy is a sustained parasitological response at six months follow-up with a final assessment at 12 months.

  • Fexinidazole: DNDi is evaluating fexinidazole as a potential new drug for Chagas disease. By September 2018, 45 patients had been recruited for this Phase II proof-of-concept study carried out in five sites in Spain to test different short-course regimens of fexinidazole for adults with chronic indeterminate Chagas. The study is now in the follow-up phase and will be completed in late 2019 with results available in 2020. If the study shows fexinidazole is effective, this will be the first new drug to treat Chagas disease in more than 50 years. 

Implementation

Implementation

Implementation and access to treatments:

 
  • Chagas Access Project: The Chagas Treatment Access project expanded its activities significantly in 2018. A new project was launched in Guatemala by DNDi with local and international partners, and a seminar held in Jutiapa to identify the main barriers and develop actions to strengthen disease control and treatment access. Another new project was launched in Brazil in partnership with the Oswaldo Cruz Foundation; seminars to address barriers were held in Rio de Janeiro and Recife. Meanwhile, the Colombian project expanded to new communities, and year 1 results showed a 997% increase in people tested and a 95% reduction in time to diagnosis in the pilot study areas. 
  • Benznidazole paediatric dosage form: The paediatric formulation of benznidazole, the main drug of choice for treating Chagas disease, was registered in Argentina in 2018. This was the result of a partnership between Fundación Mundo Sano, DNDi and Laboratorio Elea Phoenix to enable registration in more disease-endemic countries and provide a second source of the drug. The paediatric formulation of benznidazole was developed through a collaboration between DNDi and Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) of Brazil and was first registered in 2011, in Brazil. It improves accuracy, safety, and adherence to treatment for children under two years of age (or up to 20 kg). 
  • Chagas Clinical Research Platform (CCRP): With nearly 400 members from 150 institutions and 24 countries, the CCRP works to catalyse the involvement of researchers from endemic countries in improving R&D for Chagas, from drug discovery to implementation. In 2018, in a meeting in Bolivia, 95 members of the platform defined research priorities for the coming years and signed the Santa Cruz Letter, calling on governments, organizations and donors to step up their efforts to control and eliminate Chagas as a public health problem.
 

Photo credit: Rodrigo Carvalho-DNDi

Drug discovery Partnership Registration & access Translational research Chagas disease Argentina Bolivia Brazil Colombia Latin America

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo